烟酰胺核糖与紫檀芪降低非酒精性脂肪性肝病肝脏炎症标志物:一项双盲安慰剂对照临床试验
这项为期6个月的前瞻性随机双盲安慰剂对照试验在111例非酒精性脂肪性肝病患者中评估每日补充NRPT(烟酰胺核糖与紫檀芪组合)的疗效,设安慰剂、推荐剂量NRPT 1×和双倍剂量NRPT 2×三组。NRPT安全且耐受良好,主要终点肝脂肪分数较安慰剂无显著变化,但NRPT 1×组循环ALT和GGT随时间下降且较安慰剂显著,神经酰胺14:0也显著下降并与ALT下降相关,NRPT 2×组未观察到剂量依赖性效应。
要点
- NRPT推荐剂量安全且耐受良好,主要终点肝脂肪分数较安慰剂无显著变化。
- NRPT 1×组ALT和GGT随时间下降,且较安慰剂显著。
- NRPT 1×组神经酰胺14:0较安慰剂显著下降,并与该组ALT下降相关。
核心结论
- 本研究表明推荐剂量的NRPT安全,并可能有望降低非酒精性脂肪性肝病患者的肝脏炎症标志物。
研究设计与样本
- 为期6个月的前瞻性、随机、双盲、安慰剂对照临床试验,纳入111例非酒精性脂肪性肝病成人。
- 研究设三组:安慰剂组、推荐每日剂量NRPT组(NRPT 1×)和双倍剂量NRPT组(NRPT 2×)。
主要发现
- NRPT看起来安全且耐受良好。
- 研究结束时,主要终点肝脂肪分数较安慰剂未见显著变化。
- 在预设次要结局中,NRPT 1×组观察到循环肝酶丙氨酸氨基转移酶(ALT)和γ-谷氨酰转移酶(GGT)水平随时间下降,且较安慰剂显著。
- NRPT 1×组循环毒性脂质神经酰胺14:0水平较安慰剂显著下降,且该下降与该组个体ALT下降相关。
- NRPT 2×组在ALT、GGT或神经酰胺14:0方面未观察到剂量依赖性效应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed. APPROACH AND RESULTS: A 6-month prospective, randomized, double-blind, placebo-controlled clinical trial was conducted to assess the efficacy of daily NRPT (commercially known as Basis, a combination of nicotinamide riboside and pterostilbene) supplementation in 111 adults with NAFLD. The study consisted of three arms: placebo, recommended daily dose of NRPT (NRPT 1×), and a double dose of NRPT (NRPT 2×). NRPT appeared safe and well tolerated. At the end of the study, no significant change was seen in the primary endpoint of hepatic fat fraction with respect to placebo. However, among prespecified secondary outcomes, a time-dependent decrease in the circulating levels of the liver enzymes alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) was observed in the NRPT 1× group, and this decrease was significant with respect to placebo. Furthermore, a significant decrease in the circulating levels of the toxic lipid ceramide 14:0 was also observed in the NRPT 1× group versus placebo, and this decrease was associated with a decrease in ALT in individuals of this group. A dose-dependent effect was not observed with respect to ALT, GGT, or ceramide 14:0 in the NRPT 2× group. CONCLUSIONS: This study demonstrates that NRPT at the recommended dose is safe and may hold promise in lowering markers of hepatic inflammation in patients with NAFLD.
引用
- Dellinger RW, Holmes HE, Hu-Seliger T, et al. Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double-blind, placebo-controlled clinical trial. Hepatology. 2022. PMID: 36082508. doi:10.1002/hep.32778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。